Back to results
US 9,849,094 B2Granted
Eluting matrix and uses thereof
AssigneeThe General Hospital Corporation
InventorsMark Poznansky, Tao Chen
Life of this patent
Estimating the term…
Abstract
CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.
Claims16
A composition comprising at least one cell encapsulated in a CXCL12 polypeptide eluting alginate matrix, wherein the matrix is comprised of alginate polymers having an average molecular weight of about 75 kDa to about 200 kDa;
- comprises a guluronic acid to mannuronic acid ratio of no more than about 1.5;
- has an average pore size that excludes molecules that are greater than about 130 KD;
- forms a capsule having a thickness of about 200-about 500 microns;
- and
- is characterized by a release of the CXCL12 polypeptide at a rate of at least about 1.0 ng/mL/hr.
2 more elements
Dependencies are inferred from the claim text.